DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al US 20150374790A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu et al. (43) Pub. Date: Dec. 31, 2015 (54) IL-15-BASED MOLECULES AND METHODS Publication Classification OF USE THEREOF (51) Int. Cl. (71) Applicant: ALTOR BIOSCIENCE A638/20 (2006.01) CORPORATION, Miramar, FL (US) A 6LX39/395 (2006.01) A647/48 (2006.01) (72) Inventors: Bai Liu, Cooper City, FL (US); Peter (52) U.S. Cl. Rhode, Miami, FL (US), Wenxin Xu, CPC ....... A61K 38/2086 (2013.01); A61K 47/48.276 Pembroke Pines, FL (US); Hing C. (2013.01); A61K 47/48369 (2013.01); A61 K Wong, Weston, FL (US) 39/39558 (2013.01) (21) Appl. No.: 14/755,989 (22) Filed: Jun. 30, 2015 (57) ABSTRACT Related U.S. Application Data The invention features combination therapies using an IL-15 (60) Provisional application No. 62/018,899, filed on Jun. based Superagonist complex and an antibody to effectively 30, 2014. treat Subjects with cancer and infectious diseases. Patent Application Publication Dec. 31, 2015 Sheet 1 of 31 US 2015/0374790 A1 S. V d U CU 2 O A. r's O O.O1 O.1 1 10 ALT-803 (nM) Fig. 1A 50 S 40 V d 30 U g 20 3 10 O Y O O.O1 O.1 1 10 ALT-803 (nM) Fig. 1B 75 --C) - Ctrl CD4 g 60 --O- - Ctrl CD8 45 ---A--- Ctrl NK V 30 age 8O3 CD4 V 15 -- 803 CD8 U -- 8O3 NK O 3 5 7 10 CultureTime (days) Fig. 1C Patent Application Publication Dec. 31, 2015 Sheet 2 of 31 US 2015/0374790 A1 60--------------------------------------------- --K) - Ctrl CD4 Š --O-- Ctrl CD8 ---A--- Ctrl NK 3 are 803 CD4 g -- 803 CD8 S. arra 8O3 NK O 3 5 7 10 CultureTime (days) Fig. 1D 8 -o-Medium X------- S. montheme ALT-803 w do S.V U CultureTime (days) Fig.1E 2.5------------------------------------------------------------------- O 2.0----------------eas ----------------------------1----------- 1.5-------1----------------NS--(Y------------------ 3 U 1.O res. R orc) or Medium s 305 -A-ALT-803 O.O O 3 5 7 10 CultureTime (days) Fig.1F Patent Application Publication Dec. 31, 2015 Sheet 3 of 31 US 2015/0374790 A1 2.4 {d 2.0 s1. 16 W V O K) 1.2 :A V 30.8 * V V A t 04 &E C> E a O.O i? 3 n 89 n 89 CU F CU F > CC > C > CC PMBCS CD8 T cells CD4 T cells Donor 1 ADonor2 VDonor3 (>DonorA. ODOnors XDOnore Donor7 Mean SE Fig. 2A 0.2O 0.15 {d - 5. G W Se V X, 0.10 {X V S C> 0.05 : I * A A. O O o O o O.OO r ry 3 E n 3 E n 3 9CU F CU F > CC > CC > CC NK cells CD19 B cells T-reg cells DDOnOr1 ADOnOr2 VDOnors god DOnOr4 ODonors XDonoré Donor7 - Mean SE Fig.2B Patent Application Publication Dec. 31, 2015 Sheet 4 of 31 US 2015/0374790 A1 360---------------------------------------- s 100 240 mm . s 120 Q 50 S120 Y - - - - - - - - - - - - - - - - G 25 60--------------1---------- a-------- O O.O1 O.1 1 10 O O.O1 O.1 1 10 Donor-A ALT-803 (nM) Donor-B ALT-8O3 (nM) Fig. 3A Fig. 3B O 0.01 0.1 1 10 O 0.01 0.1 1 10 Donor-A ALT-803 (nM) Donor-B ALT803 (nM) Fig. 3C Fig. 3D Patent Application Publication Dec. 31, 2015 Sheet 5 of 31 US 2015/0374790 A1 O O.O1 O.1 1 10 O O.O1 O.1 1 10 ALT-803 (nM) ALT-803 (nM) Fig. 4A Fig. 4B NK cells 4000------------------------------------------ O O.O1 O.1 1 10 0 001 ol 1 10 ALT-803 (nM) ALT-803 (nM) Fig. 4C Fig. 4D Patent Application Publication Dec. 31, 2015 Sheet 7 of 31 US 2015/0374790 A1 80 Patent Application Publication Dec. 31, 2015 Sheet 8 of 31 US 2015/0374790 A1 --ALT-803 --KX-Medium 1 5 - - - - - - - - - - 10-------------- ...-- rap amm-e------------0 O:1 2:1 5:1 10:1 0:1 2:1 5:1 10:1 Fig.6AE.T Ratio Fig.6BE.T Ratio 90 s 75 is 60 C Y asO 45 ' Y -- ALT-803 30|r / Y- --K). Medium 15 - - - - - M --"e --------------------------- O O:1 2:1 5:1 10:1 E.T Ratio (with Rituximab) ALT-803 Medium Fig.6C Fig.6D Patent Application Publication Dec. 31, 2015 Sheet 9 of 31 US 2015/0374790 A1 7 5 O O O.O1 O.1 1 10 ALT-803 (nM) Fig. 7A O O.O1 O.1 1 10 ALT-803 (nM) Fig. 7B Patent Application Publication Dec. 31, 2015 Sheet 10 of 31 US 2015/0374790 A1 80 ... ' -----------------"r 80 - .is a wa was s560 "r^ ------Rituximabarea Control sg60 AA --Control...Rituximab Á40------------------------------------ 840 O O 9208 on J- G 20 O O O.O. O.O1 O. 1 1 1 O O.O. O.O1 O.1 1 1 O ALT-803 (nM) ALT-803 (nM) Fig.8A Fig.8B at-a-w/o mAb --w/o mAb 75------Rituximab -------------- s 75-------Rituximab --------------- Š 60 I-A-HOAT- - -y N 60-------------------------------- it 45- ------------------- f 45 30.- ... "NK ... 30 Non-NN 15 3 15 O O 0.01 O.1 O O.O1 0.1 ALT-803 (nM) ALT-803 (nM) Fig. 8C Fig.8D Patent Application Publication Dec. 31, 2015 Sheet 11 of 31 US 2015/0374790 A1 75------------------------------------------ 2. - - - - In vivo & 60--------------------, -, --------------------- 1. OPBS 45------------------3- ------------------- ZAlt-803 Rituximab 30|r1,r Rituximab + ALT803 15 - - - - - - - - - - - - - - - - O 2N. N: Medium Rituximab ALT-803 Rituximab + ALT8O3 In vitro treatment Fig.9A 60 -o-24D2 50- --0--ALT-803 -o-24D2 - ALT803 & 40 g 30 S ds 20 u, 10 *:p<0.05; *:pz0.001 O 24D2 (nM) 0 0001 0.01 0.1 1 10 ALT-803 (nM) O 0.0001 0.001 0.01 0.1 1 Fig.9B Patent Application Publication Dec. 31, 2015 Sheet 12 of 31 US 2015/0374790 A1 4.O 3 O 2 O 1 O O PBS ALT-803 Rituximab Rituximab + ALT803 Treatment Fig. 10 3 O 2 O 1 O O PBS Rituximab O.2 0.1 O.O5 O.O2 N-- Rituximab (10 mg/kg) and ALT-803 Fig.11 100 g 80 PBS as E.a. ALT-803 40------- Rituximab ALT-803+ & 2 Rituximab yassasssssssssssssssssssssssssss Ó 10 20 30 40 50 Study Day Fig. 12 Patent Application Publication Dec. 31, 2015 Sheet 13 of 31 US 2015/0374790 A1 e - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Survival Curve (CT26) : ALT-803 (4 ug/mouse) - : CTLA4/PD-1 (0.2 mg/mouse) 119.hiffES5 n= 4-5 (ug/mouse,(5SEESEE? mouse, totaltotal 10ludoses). doses) 199 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY -s-- PBS 8O 'in -- "v" ALT-803 a - O - ALT-803 PD-L1 5 O -Air ALT-8O3 CTLA4 aba ALT-8O3 CTLA4/PD-L1 -K-r-15 CTLA4/PD-L1 10 O O. O. O. O. O. O. O. O. O. O. O. O. O. O. O. O t- N Yn V Lr VO N OO OY O - N ryn V L? Study Days Fig. 13A VO N U survival curve (CT26) : ALT-803it-------------------- (4 ug/mouse) st 2 n 6 : a CTLA4/PD-1 (0.1 mg/mouse): ; SS rIL-15 inj:SD1-SD5/SD8-SD12: 110 (5ug/mouse, total 10 doses) ; 1 OO s as asso . - - - - - - - - - - - - - - - - - - - - - - ? is 90 --- PBS s 80 ro--- C IL15 53 | aga AT-803 E 38 -A-ALT-8O3--OCTLA4 3 - O - ALT-803+OCTLA4/PD-L1 & 29 a -v-rlL-15+OCTLA4/PD-L1 O -- O 1 O 20 30 40 50 60 7O 80 Study Day L15- ALT-803+ AT-803+ P value IL15 OCTLA4/oPDL1 AT-803 OCTLA4 OCTLA4/PD-L1 PBS 001.97 0.0012 IL15 0.0172 0.0015 IL15+0CTLA4/oPDL1 0.0089 ALT803 0.0005 ALT-803-0CTLA4 04564 Fig. 13B Patent Application Publication Dec. 31, 2015 Sheet 14 of 31 US 2015/0374790 A1 r ------------------------ ryn Survival Curve (5T33P) : ALT-803riL-15 inj(5ug/mouse (1 lug/mouse) or n y n=5 : oCTLA4/PD-L1 (0.2 mg/mouse); ---------iss----------------- 18 - -3- OCTLA4 g 39 - O - OPD-L1 is 39 ahae IL-15 60 --Va-I-15 - OCTLA4 28 ----L-15 - OPD-L1 S 30 ----- ALT-803 (0.05 mg/kg) 20 -A-ALT-803 - OCTLA4 1g &l- other ALT-803 - OPD-L1 O 10 20 30 40 50 60 Study Days Fig. 14A Survival Curve (5T33P) n n=5 ra O v - "y is --- PBS 90: t . ALT-803FP51,35g) (0.05 mg/kg) Sg - - - - - - ALT-803 (0.05 mg/kg) 40 P=0.21 i. - - - - - eles as seases - - ALT-803 (0.2 mg/kg) 9 30 --> --KX-OPD-L1 (25ug) {- A. 28 P=00021 --A-oPD-L1 (100 ug) O S. O 10 20 30 40 50 60 70 80 90 Study Day Fig.14B Patent Application Publication Dec. 31, 2015 Sheet 15 of 31 US 2015/0374790 A1 Ld-92LDTeqnL % peZeuoN % peZeuoN Ld-94LDLOOT?qnL gGI‘61 C Ln C C Ln C O O O O % peZeuoN % peZeuoN Ld-9ZLDLOOTeqnL C Ln C Ln O O % peZeuoN % peZeuoN Patent Application Publication Dec. 31, 2015 Sheet 16 of 31 US 2015/0374790 A1 : PBS E. PBS O 0.1 mg/kg ALT-803 D 0.1 mg/kg ALT-803 3 O 21 mg/kg ALT-803 21 mg/kg ALT-803 e ... als 2 O O 2. : * Day 26 Day 36 Day 26 Day 36 Fig.16A Fig.16B PBS : PBS O 0.1 mg/kg ALT-803 D 0.1 mg/kg ALT-803 60 (21 mg/kg ALT-803 340 21 mg/kgAT-803 350 s r 2S 30 S240 s 2S S 530 320 20 CU 3 5 10 10 2 s % O O 2.
Load more

Recommended publications
  • HER2 Inhibition in Gastro-Oesophageal Cancer: a Review Drawing on Lessons Learned from Breast Cancer
    Submit a Manuscript: http://www.f6publishing.com World J Gastrointest Oncol 2018 July 15; 10(7): 159-171 DOI: 10.4251/wjgo.v10.i7.159 ISSN 1948-5204 (online) REVIEW HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer Hazel Lote, Nicola Valeri, Ian Chau Hazel Lote, Nicola Valeri, Centre for Molecular Pathology, Accepted: May 30, 2018 Institute of Cancer Research, Sutton SM2 5NG, United Kingdom Article in press: May 30, 2018 Published online: July 15, 2018 Hazel Lote, Nicola Valeri, Ian Chau, Department of Medicine, Royal Marsden Hospital, Sutton SM2 5PT, United Kingdom ORCID number: Hazel Lote (0000-0003-1172-0372); Nicola Valeri (0000-0002-5426-5683); Ian Chau (0000-0003-0286-8703). Abstract Human epidermal growth factor receptor 2 (HER2)- Author contributions: Lote H wrote the original manuscript and revised it following peer review comments; Valeri N reviewed inhibition is an important therapeutic strategy in HER2- the manuscript; Chau I reviewed and contributed to the content of amplified gastro-oesophageal cancer (GOC). A significant the manuscript. proportion of GOC patients display HER2 amplification, yet HER2 inhibition in these patients has not displayed Supported by National Health Service funding to the National the success seen in HER2 amplified breast cancer. Mu- Institute for Health Research Biomedical Research Centre at ch of the current evidence surrounding HER2 has been the Royal Marsden NHS Foundation Trust and The Institute of obtained from studies in breast cancer, and we are only re- Cancer Research, No. A62, No. A100, No. A101 and No. A159; Cancer Research UK funding, No.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Immunotherapy in Various Cancers
    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
    [Show full text]
  • Or Ramucirumab (IMC-1121B) Plus Mitoxantrone and Prednisone in Men with Metastatic Docetaxel-Pretreated Castration-Resistant Prostate Cancer
    European Journal of Cancer (2015) 51, 1714– 1724 Available at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer Maha Hussain a,1,⇑, Dana Rathkopf b,1, Glenn Liu c,1, Andrew Armstrong d,1, Wm. Kevin Kelly e, Anna Ferrari f, John Hainsworth g, Adarsh Joshi h, Rebecca R. Hozak i, Ling Yang h, Jonathan D. Schwartz h,2, Celestia S. Higano j,1 a University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States b Memorial Sloan-Kettering, New York, NY, United States c University of Wisconsin, Carbone Cancer Center, Madison, WI, United States d Duke Cancer Institute and Duke Prostate Center, Duke University, Durham, NC, United States e Thomas Jefferson University, Philadelphia, PA, United States f New York University Clinical Cancer Center, New York, NY, United States g Sarah Cannon Research Institute, Nashville, TN, United States h Eli Lilly and Company, Bridgewater, NJ, United States i Eli Lilly and Company, Indianapolis, IN, United States j University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Received 11 February 2015; received in revised form 27 April 2015; accepted 10 May 2015 Available online 13 June 2015 KEYWORDS Abstract Background: Cixutumumab, a human monoclonal antibody (HuMAb), targets the Ramucirumab insulin-like growth factor receptor. Ramucirumab is a recombinant HuMAb that binds to vas- Cixutumumab cular endothelial growth factor receptor-2. A non-comparative randomised phase II study Mitoxantrone evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone (MP) in Prednisone metastatic castration-resistant prostate cancer (mCRPC).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Preclinical Efficacy of an Antibody–Drug Conjugate Targeting
    Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0449 Large Molecule Therapeutics Molecular Cancer Therapeutics Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET Anton G.T. Terwisscha van Scheltinga1,2, Annie Ogasawara1, Glenn Pacheco1, Alexander N. Vanderbilt1, Jeff N. Tinianow1, Nidhi Gupta1, Dongwei Li1, Ron Firestein1, Jan Marik1, Suzie J. Scales1, and Simon-Peter Williams1 Abstract Antibody–drug conjugates (ADC) use monoclonal antibo- and HPAF-II, or mesothelioma MSTO-211H. Ex vivo analysis dies (mAb) as vehicles to deliver potent cytotoxic drugs selec- of mesothelin expression was performed using immunohis- tively to tumor cells expressing the target. Molecular imaging tochemistry. AMA-MMAE showed the greatest growth inhibi- with zirconium-89 (89Zr)-labeled mAbs recapitulates similar tion in OVCAR-3Â2.1, Capan-2, and HPAC tumors, which targeting biology and might help predict the efficacy of these showed target-specific tumor uptake of 89Zr-AMA. The less ADCs. An anti-mesothelin antibody (AMA, MMOT0530A) was responsive xenografts (AsPC-1, HPAF-II, and MSTO-211H) did used to make comparisons between its efficacy as an ADC and not show 89Zr-AMA uptake despite confirmed mesothelin its tumor uptake as measured by 89Zr immunoPET imaging. expression. ImmunoPET can demonstrate the necessary deliv- Mesothelin-targeted tumor growth inhibition by monomethyl ery, binding, and internalization of an ADC antibody in vivo auristatin E (MMAE), ADC AMA-MMAE (DMOT4039A), andthiscorrelateswiththeefficacy of mesothelin-targeted ADC was measured in mice bearing xenografts of ovarian cancer in tumors vulnerable to the cytotoxic drug delivered. Mol Cancer OVCAR-3Â2.1, pancreatic cancers Capan-2, HPAC, AsPC-1, Ther; 16(1); 134–42.
    [Show full text]
  • Patient Resource Free
    PATIENT RESOURCE FREE Third Edition CancerUnderstanding Immunotherapy Published in partnership with CONTENT REVIEWED BY A DISTINGUISHED PRP MEDICAL PATIENT ADVISORY RESOURCE BOARD PUBLISHING® Understanding TABLE OF CONTENTS Cancer Immunotherapy Third Edition IN THIS GUIDE 1 Immunotherapy Today 2 The Immune System 4 Immunotherapy Strategies 6 Melanoma Survivor Story: Jane McNee Chief Executive Officer Mark A. Uhlig I didn’t look sick, so I didn’t want to act sick. Publisher Linette Atwood Having and treating cancer is only one part of your life. Co-Editor-in-Chief Charles M. Balch, MD, FACS Jane McNee, melanoma survivor Co-Editor-in-Chief Howard L. Kaufman, MD, FACS Senior Vice President Debby Easum 7 The Road to Immunotherapy Vice President, Operations Leann Sandifar 8 Cancer Types Managing Editor Lori Alexander, MTPW, ELS, MWC™ 14 Side Effects Senior Editors Dana Campbell Colleen Scherer 15 Glossary Graphic Designer Michael St. George 16 About Clinical Trials Medical Illustrator Todd Smith 16 Cancer Immunotherapy Clinical Trials by Disease Production Manager Jennifer Hiltunen 35 Support & Financial Resources Vice Presidents, Amy Galey Business Development Kathy Hungerford 37 Notes Stephanie Myers Kenney Account Executive Melissa Amaya Office Address 8455 Lenexa Drive CO-EDITORS-IN-CHIEF Overland Park, KS 66214 For Additional Information [email protected] Charles M. Balch, MD, FACS Advisory Board Visit our website at Professor of Surgery, The University of Texas PatientResource.com to read bios of MD Anderson Cancer Center our Medical and Patient Advisory Board. Editor-in-Chief, Patient Resource LLC Editor-in-Chief, Annals of Surgical Oncology Past President, Society of Surgical Oncology For Additional Copies: To order additional copies of Patient Resource Cancer Guide: Understanding Cancer Immunotherapy, Howard L.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]